CA2630262C - The use of isothiocyanates compounds in treating prostatic diseases and skin cancer - Google Patents

The use of isothiocyanates compounds in treating prostatic diseases and skin cancer Download PDF

Info

Publication number
CA2630262C
CA2630262C CA2630262A CA2630262A CA2630262C CA 2630262 C CA2630262 C CA 2630262C CA 2630262 A CA2630262 A CA 2630262A CA 2630262 A CA2630262 A CA 2630262A CA 2630262 C CA2630262 C CA 2630262C
Authority
CA
Canada
Prior art keywords
peitc
isothiocyanates
oil
isothiocyanate
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2630262A
Other languages
English (en)
French (fr)
Other versions
CA2630262A1 (en
Inventor
Jingcai Cheng
Jenwei Chiao
Haiya Jin
Chengjuan Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi JC Pharmaceutical Tech Co Ltd
Original Assignee
Wuxi JC Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200510095737 external-priority patent/CN1769268A/zh
Priority claimed from CNA2006100381121A external-priority patent/CN1840196A/zh
Application filed by Wuxi JC Pharmaceutical Tech Co Ltd filed Critical Wuxi JC Pharmaceutical Tech Co Ltd
Publication of CA2630262A1 publication Critical patent/CA2630262A1/en
Application granted granted Critical
Publication of CA2630262C publication Critical patent/CA2630262C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2630262A 2005-11-15 2006-11-14 The use of isothiocyanates compounds in treating prostatic diseases and skin cancer Active CA2630262C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN 200510095737 CN1769268A (zh) 2005-11-15 2005-11-15 一种天然及人工合成的异硫氰酸酯类化合物jc－5411在制备转录因子sp1的抑制剂中的应用
CN200510095737.7 2005-11-15
CNA2006100381121A CN1840196A (zh) 2006-01-27 2006-01-27 一种适用于难溶性药物的分散剂
CN200610038112.1 2006-01-27
PCT/CN2006/003062 WO2007056941A1 (fr) 2005-11-15 2006-11-14 Utilisation de composes a base d'isothiocyanates dans le traitement de maladies prostatiques et du cancer de la peau

Publications (2)

Publication Number Publication Date
CA2630262A1 CA2630262A1 (en) 2007-05-24
CA2630262C true CA2630262C (en) 2011-11-08

Family

ID=38048290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2630262A Active CA2630262C (en) 2005-11-15 2006-11-14 The use of isothiocyanates compounds in treating prostatic diseases and skin cancer

Country Status (7)

Country Link
US (2) US8039511B2 (de)
EP (2) EP2441454B1 (de)
JP (1) JP5308160B2 (de)
AT (1) ATE552000T1 (de)
CA (1) CA2630262C (de)
DK (2) DK1961418T3 (de)
WO (1) WO2007056941A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8665785B2 (en) * 2009-09-11 2014-03-04 Enversa Companies, Llc Systems and methods for establishing a telecommunications bridge between a user device and a node
CN102160872A (zh) 2010-02-23 2011-08-24 天津天士力制药股份有限公司 复方丹参滴丸胶囊
US8414869B2 (en) * 2010-11-30 2013-04-09 N.V. Perricone Llc Melanin promoting topical composition
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en) * 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
TWI495464B (zh) * 2013-02-08 2015-08-11 Univ Nat Taiwan 苦味化合物於活化ｇｌｐ－１分泌之用途
US10010520B2 (en) 2013-08-13 2018-07-03 Jc (Wuxi) Company, Inc. Combined application of isothiocyanate compound and anti-cancer medicine
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
JP2020534272A (ja) * 2017-09-15 2020-11-26 タイム，インコーポレーテッド 経皮製剤
DE102018121251A1 (de) * 2018-08-30 2020-03-05 Shenstone Consultants Ltd. Isothiocyanate
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
US20220378670A1 (en) 2019-07-10 2022-12-01 Nanometics Llc (D.B.A. Phd Biosciences) Polyurethane gels
US11534389B2 (en) 2019-08-30 2022-12-27 Grant Industries, Inc Bio-based and biodegradable elastomer for cosmetic and personal care
IT201900025840A1 (it) * 2019-12-31 2021-07-01 Univ Bologna Alma Mater Studiorum Composti isotiocianati e isoselencianati
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052351A1 (en) * 2002-12-06 2004-06-24 Dsm Ip Assets B.V. Novel use of lycopene
US20050070602A1 (en) * 2003-09-30 2005-03-31 Jen-Wei Chiao Method of modulating immune response by administration of immuno-activation agent
CN100448845C (zh) 2005-06-30 2009-01-07 无锡杰西医药科技有限公司 一种天然及人工合成的异硫氰酸酯类化合物jc－5411在制备预防和治疗前列腺癌、肝癌、胃癌、肺癌、乳腺癌、宫颈癌、黑色素瘤和神经母细胞瘤的药物中的应用
US20100204319A1 (en) * 2006-10-17 2010-08-12 Summa Development Limited Treatment for benign prostatic hyperplasia

Also Published As

Publication number Publication date
EP1961418A4 (de) 2009-09-02
WO2007056941A1 (fr) 2007-05-24
US20120046358A1 (en) 2012-02-23
JP2009515910A (ja) 2009-04-16
US8039511B2 (en) 2011-10-18
JP5308160B2 (ja) 2013-10-09
DK1961418T3 (da) 2012-07-23
US8410170B2 (en) 2013-04-02
DK2441454T3 (en) 2015-12-21
EP2441454A1 (de) 2012-04-18
CA2630262A1 (en) 2007-05-24
EP1961418A1 (de) 2008-08-27
EP1961418B1 (de) 2012-04-04
EP2441454B1 (de) 2015-09-16
ATE552000T1 (de) 2012-04-15
US20090005438A1 (en) 2009-01-01

Similar Documents

Publication Publication Date Title
CA2630262C (en) The use of isothiocyanates compounds in treating prostatic diseases and skin cancer
CN101091705B (zh) 异硫氰酸酯类化合物在前列腺疾病及皮肤癌中的应用
KR100741723B1 (ko) 암 예방을 위한 하이드록시마타이레지놀
Lei et al. Camellia oil (Camellia oleifera Abel.) attenuates CCl 4-induced liver fibrosis via suppressing hepatocyte apoptosis in mice
US20100297230A1 (en) Compositions and methods for prostate and menstrual/menopausal related health
JP2006508942A (ja) アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
Aldaddou et al. Ameliorative effect of methanolic extract of Tribulus terrestris L. on nicotine and lead-induced degeneration of sperm quality in male rats
Akram et al. A newly synthesized macakurzin C-derivative attenuates acute and chronic skin inflammation: The Nrf2/heme oxygenase signaling as a potential target
US10688146B2 (en) Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems
EP3328498B1 (de) Medizinisches kit enthaltend kräuterkombinationen zur behandlung von psoriasis
JP2012520301A (ja) エストロゲン化合物及びその使用方法
Feki et al. Thymelaea hirsuta extract attenuates testosterone-induced benign prostatic hyperplasia in rats: Effect on oxidative stress, inflammation and apoptosis
KR102628223B1 (ko) 노르갈란타민을 포함하는 간 손상의 예방 또는 치료용 조성물
US20130288989A1 (en) New use of chemical ingredients in cynomorium as phytoestrogen
KR101351406B1 (ko) 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 동맥경화 예방 및 치료용 조성물
RU2803241C2 (ru) КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ 7β-ГИДРОКСИХОЛЕСТЕРИН И ЛИПИДНЫЙ НОСИТЕЛЬ, И ЕЕ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ НЕОПЛАСТИЧЕСКИХ ПАТОЛОГИЙ
Muszalska Advancements in the prevention and treatment of benign prostatic hyperplasia, with particular emphasis on fireweed (Epilobium angustifolium L.) and nettle (Urtica dioica L.). A review.
RU2773173C2 (ru) Применение олеорезинов копаиферы при патологиях простаты
Liu et al. A comprehensive review of Ilex hainanensis Merr.: Traditional uses, chemical composition, pharmacological properties, toxicity and clinical applications
Saravanan et al. In vitro and In silico Cytotoxic Activity of Aconitum heterophyllum Phytoniosomes and its Ethanolic Root Extract: A Comparative Study.
Dutta et al. Effect of the leaves of Psidium guajava Linn. on experimentally induced colitis in animal models
Hunsakunachai Pharmacokinetic Study Of Cucurbitacin B From Trichosanthes Cucumerina L. In Rats

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250514